Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06102434 · ClinicalTrials.gov registry record · Early Phase 1
Safety Profile of Psilocybin for Cocaine Use Disorder
A Early Phase 1 study of Cocaine Use Disorder, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06102434: Recruiting Early Phase 1 study of Cocaine Use Disorder, sponsored by University of California, Los Angeles.
NCT06102434 is a Early Phase 1 study of Cocaine Use Disorder that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 10 participants, below the 103-participant average among 26 other Cocaine Use Disorder trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06102434, a Early Phase 1 study of Cocaine Use Disorder, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to establish the safe administration of psilocybin in individuals with cocaine use disorder in terms of cardiovascular (e.g., heart rate) and subjective (e.g., mood) effects. The study's subject population consists of men and women between the ages of 21 and 55 from the Los Angeles area that meet criteria for cocaine use disorder and express an interest in ceasing cocaine use. 25 mg oral psilocybin will be administered to 10 individuals (separately) during a single laboratory visit. The laboratory visit will take place from 9 am until 3 pm within a comfortable, living room like environment. Within this study session room, participants will be accompanied by two clinicians. Participants will then consume the psilocybin capsule, and thereafter will be encouraged to lie down on a couch and introspect on the experience. At one-hour intervals following ingestion, participants will be tested briefly for changes in heart rate, blood pressure, and subjective effects. No blood draws, behavioral assessments, or neuroimaging is included in the study. Following the laboratory visit, investigators will check-in on participants remotely, after 48 hours, and 10, 50, and 90 days from the psilocybin session.
Conditions Studied
Interventions
- DRUG Psilocybin
Study Locations (1)
California
- University of California, Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2026-06 |
| Phase | Early Phase 1 |
What NCT06102434 shows while recruiting
NCT06102434 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 103-participant average among 26 other Cocaine Use Disorder trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Cocaine Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.
NCT06102434 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06102434 about?
NCT06102434 is a clinical study titled "Safety Profile of Psilocybin for Cocaine Use Disorder". The purpose of this study is to establish the safe administration of psilocybin in individuals with cocaine use disorder in terms of cardiovascular (e.g., heart rate) and subjective (e.g., mood) effects. The study's subject population consists of men and women between the ages of 21 and 55 from the ...
What is the current status of trial NCT06102434?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2026-02-01. Estimated completion is 2026-06.
What conditions does trial NCT06102434 study?
This clinical trial studies the following conditions: Cocaine Use Disorder.
What interventions are being tested in trial NCT06102434?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT06102434?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06102434 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06102434's enrollment target sits among peer trials
10 26th of 26 higher than 1 of 26 other Cocaine Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cocaine Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cocaine and Pentoxifylline (BED IN 47)
RECRUITING · Early Phase 1
-
Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)
RECRUITING · Early Phase 1
-
Imaging CRF X NOP Interactions in CUD
RECRUITING · Early Phase 1
-
[C-11]NPA PET-amphetamine in Cocaine Use Disorders
RECRUITING · Early Phase 1
-
Targeting Drug Memories With Methylphenidate
ACTIVE NOT RECRUITING · Early Phase 1
-
[11C]NOP-1A and Cocaine Use Disorders
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI